Powerful story-telling is the best route to achieve patient access.
DeltaShift your story with
The evidence dossier that payers and local affiliates actually want to read and use.
Creates the big picture perspective from a copious amount of complex content and data.
Transforms evidence into powerful presentations that persuades and inspires people to act.
It is time for a brand new chapter.
Payers are demanding communication to be transparent, relatable, succinct and easily accessible for decision-making.
AESARA has the vision to DeltaShift your scientific evidence into a meaningful story for audiences, digitally.
What Our Clients Have to Say
“Sissi and her team provide a unique blend of technical HEOR expertise, strategic thinking and “roll up your sleeves” implementation. I trust them to be a thinking partner — contributing towards resolving whatever question I am facing globally, regionally or locally.”
“After several years and numerous engagements, I can say that Sissi and her team run some of the best meetings in industry. They listen well to each stakeholder’s needs and are committed to making sure our content is rigorous yet engaging. From the months of planning upfront to the final details after the meeting — simply put, they get it done.”
“The insight and support from AESARA helped us strategically and tactically align our WW HEOR capability to succeed in a highly competitive environment.”
“I am very passionate to partner with AESARA because they have a unique business model of HEOR expertise and innovative digital solutions to meet our needs. Their delivery and execution is top notch and I can consistently count on them to help us navigate the complexities of the healthcare landscape.”
“I have interacted with AESARA on a strategic project to sketch out the future & roadmap for EU+ Region Field Market Access. Ohene Asare’s team has expertise in strategy planning & operationalization in commercialization of products to lifecycle management for small, mid-sized and large pharmaceuticals and Biotechs within the US and ROW markets.